Cargando…

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Detalles Bibliográficos
Autores principales:	Sposito, Andrei C., Berwanger, Otávio, de Carvalho, Luiz Sérgio F., Saraiva, José Francisco Kerr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396451/ https://www.ncbi.nlm.nih.gov/pubmed/30823882 http://dx.doi.org/10.1186/s12933-019-0825-1

Ejemplares similares

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2018)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Correction to: “Differing functional mechanisms underlie cognitive control deficits in psychotic spectrum disorders”
Publicado: (2022)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Correction to: Exosomes in Cardiovascular Medicine
por: Dykes, Iain M.
Publicado: (2018)

Correction to: Diabetes, cardiovascular disease and the microcirculation
por: Strain, W. David, et al.
Publicado: (2021)

Correction to: Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention
por: Volpe, Massimo, et al.
Publicado: (2022)

Correction to: Updates on cardiovascular outcome trials in diabetes
por: Schnell, Oliver, et al.
Publicado: (2017)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Correction to: Relationship between Azithromycin and Cardiovascular Outcomes in Unvaccinated Patients With COVID‐19 and Preexisting Cardiovascular Disease
Publicado: (2023)

Correction to: “Obesity and contraceptive use: impact on cardiovascular risk”
Publicado: (2023)

Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2021)

Correction to: Association of Cardiovascular Risk Burden With Risk and Progression of Disability: Mediating Role of Cardiovascular Disease and Cognitive Decline
Publicado: (2020)

Do Changes in Innate Immunity Underlie the Cardiovascular Benefits of Exercise?
por: Chuong, Phillip, et al.
Publicado: (2019)

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
por: Saraiva, José Francisco Kerr, et al.
Publicado: (2021)

Correction: Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome
por: Béziat, Vivien, et al.
Publicado: (2020)

Correction to: TMEM63C mutations cause mitochondrial morphology defects and underlie hereditary spastic paraplegia
Publicado: (2022)

Correction: Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis
Publicado: (2018)

Correction to: Cardiovascular risk factors and body composition in adults with achondroplasia
por: Fredwall, Svein O., et al.
Publicado: (2021)

Correction to: Cardiovascular disease (CVD): assessment, prediction and policy implications
por: Rehman, Shazia, et al.
Publicado: (2021)

Correction to: Locking the Revolving Door: Racial Disparities in Cardiovascular Disease
Publicado: (2023)

Correction to: Radiation‐Induced Cardiovascular Disease: Review of an Underrecognized Pathology
Publicado: (2023)

Correction: TSPAN6 is a suppressor of Ras-driven cancer
por: Humbert, Patrick O., et al.
Publicado: (2022)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment
por: Hippe, Andreas, et al.
Publicado: (2021)

Correction: Shared acoustic codes underlie emotional communication in music and speech—Evidence from deep transfer learning
por: Coutinho, Eduardo, et al.
Publicado: (2018)

Correction: Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO)
por: Cox, Allison J., et al.
Publicado: (2017)

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?
por: Melo, Miguel, et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

Editorial: Beyond Cardiovascular Disease: Challenging New Pathways in Lipid and Lipoprotein Metabolism
por: Passarelli, Marisa, et al.
Publicado: (2022)

Correction: The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease
por: Borràs Sans, Mercè, et al.
Publicado: (2018)

Primary Prevention of Cardiovascular Disease at Community Clinics in the State of Sao Paulo, Brazil: Results from the Epidemiological Information Study of Communities
por: Fonseca, Henrique Andrade R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_48bjk5dbt3sh6ol45pk4kbd22g